<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003648</url>
  </required_header>
  <id_info>
    <org_study_id>NCCTG-974655</org_study_id>
    <secondary_id>CDR0000066737</secondary_id>
    <nct_id>NCT00003648</nct_id>
  </id_info>
  <brief_title>Genetic Study of Patients and Families With a History of Colorectal Cancer</brief_title>
  <official_title>The Familial Colorectal Neoplasia Collaborative Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Determination of genetic markers for colorectal cancer may help doctors to&#xD;
      identify patients who are at risk.&#xD;
&#xD;
      PURPOSE: Genetic testing study of patients and families with a history of colorectal cancer&#xD;
      to identify patients who are at risk of developing colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Select patients with colon cancer and families at high-risk for colon cancer&#xD;
      and collect leukocyte DNA, immortalized cell lines, plasma, and tumor specimens from these&#xD;
      individuals and from control individuals. II. Develop patient education, counseling, and&#xD;
      follow up plans for these individuals. III. Compare the frequency of defective DNA mismatch&#xD;
      repair in individuals with familial colon cancer versus all colon cancers by using antibodies&#xD;
      to the hMSH2 and hMLH1 protein products.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients, family members, and control individuals&#xD;
      complete an extended telephone interview, an extended personal interview, and an&#xD;
      epidemiological survey, and contribute a blood specimen. Blood and tumor specimens are&#xD;
      examined for the specific pattern of immunohistochemical expression of hMSH2 and HMLH1 to&#xD;
      determine the frequency or lack of expression of these two protein products. Patients may be&#xD;
      contacted periodically (about every 3 years) to update information about health, health&#xD;
      practices, and family history. Patients do not receive the results of the genetic testing and&#xD;
      the results do not influence the type or duration of treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: At least 500-600 families (approximately 1500 patients) and the same&#xD;
      number of matched controls will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>frequency of defective DNA mismatch repair in individuals with familial colon cancer versus all colon cancers by using antibodies to the hMSH2 and hMLH1 protein products</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1500</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Patients, family members, and control individuals complete an extended telephone interview, an extended personal interview, and an epidemiological survey, and contribute a blood specimen. Blood and tumor specimens are examined for the specific pattern of immunohistochemical expression of hMSH2 and HMLH1 to determine the frequency or lack of expression of these two protein products. Patients may be contacted periodically (about every 3 years) to update information about health, health practices, and family history. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA stability analysis</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene rearrangement analysis</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and tumor samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with colorectal cancer previously enrolled on NCCTG-784852,&#xD;
        NCCTG-794751, NCCTG-844652, NCCTG-874651, NCCTG-894651, or NCCTG-914653.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Primary colorectal cancer and participating in one of the&#xD;
        following NCCTG protocols: NCCTG-784852: No Treatment Control Versus Levamisole Versus&#xD;
        Levamisole Plus 5-Fluorouracil NCCTG-794604: No Treatment Control Versus 5-FU by Portal&#xD;
        Vein Infusion NCCTG-794751: Postoperative Radiation Versus Postoperative Radiation Plus&#xD;
        Sequential Chemotherapy with Methyl CCNU and 5-FU NCCTG-844652: An Intergroup Study - An&#xD;
        Evaluation of Levamisole Alone or Levamisole Plus 5-Fluorouracil as Surgical Adjuvant&#xD;
        Treatment for Resectable Adenocarcinoma of the Colon NCCTG-864751: Phase III Protocol for&#xD;
        Surgical Adjuvant Therapy of Rectal Carcinoma: A Controlled Evaluation of (A)&#xD;
        Protracted-Infusion-5-Fluorouracil (5-FU) as a Radiation Enhancer and (B) 5-FU Plus&#xD;
        Methyl-CCNU Chemotherapy NCCTG-874651: M/N - A Controlled Evaluation of Recombinant&#xD;
        Interferon-Gamma (IFN-GM) and 5-FU and Folinic Acid With or Without Levamisole as Adjuvant&#xD;
        Treatment for Resectable Adenocarcinoma of the Colon NCCTG-894651: A Controlled Phase III&#xD;
        Evaluation of 5-Fluorouracil with Levamisole and Leucovorin as Adjuvant Treatment for&#xD;
        Resectable Colon Cancer NCCTG-914653: A Phase III Evaluation of High-Dose Levamisole Plus&#xD;
        5-Fluorouracil and Leucovorin as Surgical Adjuvant Therapy for High-Risk Colon Cancer&#xD;
        Adequate tissue for review OR Families of patients meeting the above criteria OR Colon&#xD;
        cancer patient and population controls not in a high-risk family OR Spouse of a high-risk&#xD;
        colon cancer patient&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Not specified Performance status: See Disease Characteristics&#xD;
        Life expectancy: See Disease Characteristics Hematopoietic: See Disease Characteristics&#xD;
        Hepatic: See Disease Characteristics Renal: See Disease Characteristics&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noralane M. Lindor, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Scottsdale Oncology Program</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cedar Rapids Oncology Project</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403-1206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Iowa Oncology Research Association</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309-1016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology-Oncology</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101-1733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraCare Clinic</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medcenter One Health System</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid City Regional Hospital</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Sioux Community Cancer Consortium</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>October 28, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2003</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage I rectal cancer</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

